China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
415 Views
Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates
Shanghai Junshi Bioscience Co. Ltd. (1877 HK) was listed on December 2018 and recorded a stellar debut performance thanks to the NDA approval for...
421 Views
ECM Weekly (22 Jun 2019) - Alibaba, Budweiser Brewing Co, Ascentage, CIMC Vehicle, Impro Precision
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
536 Views
Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)
Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...
736 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
584 Views